理查德·达利于2015年2月加入了我们的董事会。直到2014年10月，Daly先生担任Astrazeneca美国糖尿病总统，在那里他领导所有商业和医疗计划和目标为11000亿美元，包括成功发射孤儿/稀有紊乱药物，Myalept，用于脂肪蓄水池。从2011年到2013年，Daly先生担任萨奇帕伙伴的联合创始人，是一家提供制药行业的公司提供外包商业服务的公司。From 2008 to 2011, Mr. Daly was employed by Takeda N.A., the North American subsidiary of Takeda Pharmaceuticals, serving first as Vice President, Integration, leading a 6,500 person commercial/R&D merger between TAP Pharmaceuticals and Takeda N.A., then as Executive Vice President of Takeda N.A., with commercial responsibility for all businesses in the Americas. From 2006 to 2008, Mr. Daly served as the Vice President, Commercial Strategy for TAP Pharmaceuticals, a joint venture between Takeda Pharmaceuticals and Abbott Labs. In 1998, Mr. Daly was a founding member of the leadership team of Takeda Pharmaceuticals N.A., serving initially as the Senior Director of Marketing. Between 1998 and 2006, Mr. Daly took on roles of increasing responsibility culminating in his appointment as Senior Vice President, Marketing (2001-2006). Mr. Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998.